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acteristics were comparable between the two cohorts (all p-values0.05). During
median follow-up of 2.95 years, the cumulative incidence of deathwas 304 (17.72%)
among 1716 PADT patients and 94 (5.48%) among 1716 RP patients; 66 (3.85%) and 2
(0.12%) for prostate cancer specific deaths, respectively. The PADT group had
nearly 4 times higher overall mortality risk compared to those using RP (odds ratio
(OR)3.534, 95% confidence interval (CI)2.801-4.464, p0.001). Furthermore, pa-
tients who received PADT had significantly higher prostate cancer specific mortal-
ity compared to those using RP (OR30.875, 95% CI7.535-126.506, p0.001).
CONCLUSIONS: Overall mortality and prostate cancer specific mortality following
PADT were significantly higher compared to those following RP among localized
prostate cancer patients. These data do not support the use of PADT in men with
clinically localized prostate cancer.
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OBJECTIVES: Often new treatment options lack comparisons to treatment options
which already exist on themarket andwhichwere launched several years ago. Due
to such a lack of head-to-head evidence indirect treatment comparisons (ITC) are
increasingly being performed. Although ITC methods are widely accepted, the re-
sults are often interpreted with caution, probably because of their lack of external
validity proven by real clinical studies.METHODS:The first available pivotal phase-
III trials for docetaxel and erlotinib in second-line non-small cell lung cancer
(NSCLC) included best supportive care (BSC) as a comparator which allowed an ITC
of erlotinib versus docetaxel to be performed, applying the Bucher methodology.
The pemetrexed pivotal phase-III trial provided direct evidence vs docetaxel,
which subsequently allowed an ITC of erlotinib vs pemetrexed to be performed.
Later another phase-III trial was published comparing erlotinib vs pemetrexed,
which allowed the ITC of erlotinib vs docetaxel to be re-performed. This trial and a
further recently published phase-III trial directly comparing erlotinib vs docetaxel
or pemetrexed, allowed the external validation of the ITC outcomes. The overall
survival (OS) hazard ratios (HR) were used to produce ITC-OS HRs with 95% confi-
dence intervals (95%CI). RESULTS: Comparing erlotinib versus docetaxel resulted
in an ITC-OS HR of 1.25 (95%CI: 0.76-2.06, p0.381). Using these ITC results to
compare erlotinib to pemetrexed resulted in an ITC-OSHR of 1.26 (95%CI: 0.74-2.15,
p0.392). Re-performing the ITC of erlotinib versus docetaxel resulted in an ITC-OS
HR of 0.95 (95%CI: 0.71-1.28, p0.736). The head-to-head evidence validated those
findingswith anOSHR of 0.96 (95%CI: 0.77-1.21, p0.916) and 0.96 (95%CI: 0.78-1.19,
p0.730), comparing erlotinib vs pemetrexed and erlotinib versus pemetrexed or
docetaxel, respectively. CONCLUSIONS: Recently published clinical head-to-head
evidence has confirmed the appropriateness and validity of ITC findings in second-
line NSCLC.
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OBJECTIVES: In the past, interferon (IFN) has proven to be effective in extending
the survival of patients with RCC. New TT, drugs such as Sunitinib (SU), Sorafenib
(SO) and Bevacizumab (BE) have been tested against IFN. Recently, a new studywas
published, comparing a new TT, Pazopanib (PZ) versus placebo (PLA) but not inter-
feron. An important question arose about the relative efficacy of PZ versus other TT
and IFN, given that the control group used was not an active one in the PZ trial.
When head-to-head studies are lacking; an ICMA can help solving the problem of
relative efficacy. Our aim was to perform an ICMA comparing TT. METHODS: We
performed a systematic review, searching for randomized controlled trials that
compared TT against IFN or PLA, or those that compared PLA versus IFN. We
conducted an indirect comparisonmeta-analysis that used PLA as a bridge to com-
pare the different TT. The end point of interest was progression free survival (PFS).
The results are expressed as Hazard Ratio (HR), with the corresponding confidence
interval of 95% (CI). RESULTS:We found 8 randomized controlled trials that fit our
inclusion criteria. The results of the ICMA for PFSwere: PZ versus SU [HR 1.19; CI
0.37 to 3.85]; PZ versus IFN [HR0.59; CI 0.23 to 1.55]; PZ versus SO [HR0.75; CI
0.22 to 2.54]; PZ X BE [HR0.83; CI0.31 to 2.24] CONCLUSIONS: The results showed
that PZ was superior to placebo but not to IFN. The confidence intervals obtained
from the analysis were very wide precluding a definitive conclusion regarding the
relative efficacy of TT, although there was a trend to confirm the superiority of SU.
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OBJECTIVES: Study examined the pattern of chemotherapy and biologic therapy
use by line of treatment in newly diagnosed patients with colorectal cancer (CRC).
METHODS: Patients newly diagnosed with CRC between January 1, 2005 and June
31, 2009 and treated with systemic therapy were identified in a US-based admin-
istrative medical claims (i3 Innovus) database. Six months of patient history with
no prior ICD-9 diagnosis of CRC and 1-year post-index continuous enrollment was
required. Patients were followed from initial CRC diagnosis to death, disenroll-
ment, or June 31, 2010. Chemotherapy and biologic treatments over time were
analyzed to identify lines of therapy and assessed and stratified by line of therapy
(1st, 2nd, 3rd ), subgroup analysis was performed in metastatic CRC. RESULTS: Of
9876 patients, 45% received only 1st line treatment, 35% received 1st and 2nd line
treatment and 20% received 3rd line and beyond. 60% of the study patients were
identified as having metastasis either during the follow up period or at index date.
The 1st line, 43% received an oxaliplatin-based regimen, 5% received an irinotecan-
based regimen, and 46% received 5-FU alone. 2nd and 3rd line settings percentages
of patients treated with irinotecan-based regimens increased from 18% to 43%,
respectively, use of oxaliplatin-based regimens dropped from 42% to 22%, respec-
tively. The proportion of subjects who used bevacizumab doubled from 1st to 3rd
line regimen. Overall, use of cetuximab and panitumumab increased from 2% in
the 1st line to 7%, and 23%, respectively in the 2nd and 3rd  lines of treatment.
CONCLUSIONS: Despite treatment guidelines, a large proportion of patients re-
ceived 5-FUmonotherapy and capecitabine as 1st line treatment even for metaste-
ses. The use of biologics in the first line was present with use in later lines. The use
of EGFR inhibitors increased in the later lines of treatment after FOLFOX and FOL-
FIRI with or without bevacizumab.
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OBJECTIVES: Stage IV CRC patients have varying survival results from multiple
lines of treatment. The objective of this study was to evaluate in a real world
context, the impact of adding a third line of chemotherapy to a stage IV CRC
population. METHODS: The Georgia Cancer Specialist database (2005-2011) was
used. Patients with stage IV colon or rectal cancer and treated with chemotherapy
were followed from initial CRC diagnosis until death, study end or lost to follow-up.
Patientswere stratified into lines and type of protocol for treatments. Kaplan-Meier
curves were used to compare the overall survival results between lines of therapy.
RESULTS: There were 335 patients with confirmed stage IV CRC of which 35%
received one protocol, 27% two protocols, and 38% received three or more proto-
cols. The most common first line agents consisted of FOLFOX with or without
bevacizumab or FOLFIRI with or without bevacizumab. Some single agent 5FU or
5FUwith bevacizumabwas observed in first line. Themost common second agents
were the FOLFOX or FOLFIRI not given in first line. However single agent capecit-
abine, cetuximab and bevacizumab were observed. In third line similar single
agents but more panitumumab and capecitabine combinations were observed. Of
those treated with second line (45) and three or more lines (75). The median sur-
vival was no different between the patients that received second line and those
that went on to a third line (Log-Rank P0.1249). CONCLUSIONS: The addition of
adding a third line to a stage IV population that already received a second line failed
show an association to increase survival. The benefit of adding a third line may
benefit some patients and the particular combination of therapy needs to be ex-
plored in future studies.
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OBJECTIVES: To compare the economic impact from US societal perspective of
Nilotinib and Dasatinib as second-line therapies in treatment of CML patients with
Imatinib resistance or intolerance by conducting a cost-effectiveness analysis.
METHODS: A Markov simulation model was developed to estimate quality ad-
justed life years (QALYs) and expected costs using data from head-to-head com-
parative clinical trials. Costs in the model included medication cost, hospitaliza-
tion cost, physician fee, laboratory test fee, adverse events cost, and value of
waiting time and were obtained from published literature and government and
organization websites. All costs were adjusted to 2011 US dollars. The treatment
pattern was assumed to be 800mg/day for Nilotinib, or 100mg/day for Dasatinib in
the chronic phase and 140mg/day in the advancedphase. Treatmentwas evaluated
up to progression of the disease, best supportive care and up to death, operating 80
cycles of 3 months. Switching from one product to the other due to severe adverse
eventswas also considered. Sensitivity analyseswere performed to test the robust-
ness of the results. RESULTS: In the base case analysis, the total cost for treatment
with Nilotinib was $150,966, and Dasatinib was $126,672. Patients treated with
Nilotinib gained 0.57more life years, or 0.49moreQALYs, comparedwithDasatinib.
The incremental cost-effectiveness ratio (ICER) for Nilotinib therapy was $49,467/
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